BE-101
Hemophilia B
Phase 1/2Active
Key Facts
About Be Biopharma
Be Biopharma is a private, clinical-stage biotech based in Cambridge, MA, developing Engineered B Cell Medicines (BCMs). The company has advanced its lead candidate, BE-101 for hemophilia B, into a Phase 1/2 clinical trial (BeCoMe-9) and is building a broader pipeline, including BE-102 for hypophosphatasia. Backed by over $260 million from a syndicate of top-tier life science investors, Be Bio aims to leverage the natural biology of B cells to create a new modality for protein replacement and beyond.
View full company profileTherapeutic Areas
Other Hemophilia B Drugs
| Drug | Company | Phase |
|---|---|---|
| CSL889 (Etranacogene Dezaparvovec) | CSL | Phase 3 |